Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI -- Ignore unavailable to you. Want to Upgrade?

To: JanyBlueEyes who wrote (1328)	3/15/1998 4:03:00 PM
From: rogermci®	Read Replies (1) \| Respond to of 5736

Interesting post from AOL MF board on CCSI vs SPRX technology: Subject: CCSI(D) Today Date: Sun, Mar 15, 1998 14:34 EST From: BumperB Message-id: Answer: Depends if you are Joker or a Penguin or whatever. ---------------------------------------- A very interesting scientific study worth reading and published in the CCC Journal-Cancer Causes & Control-Childhood Leukemia Following Phototherapy for Neonatal Hyperbilirubinemia (Denmark). Jorgen Helge Olsen, Henrik Hertz, et al July 1996, Page 411. The above paper reports on an epidemiological study that was undertaken to determine if photosensitizing (phototherapy) lighting on neonates is responsible for the steady increase in the incidence of ALL seen in the USA during the past 2 decades. The study was initiated to challenge several other studies (all cited) that empiricaly found a direct correlation between the incidence of chilhood leukemia and phototherapy treatment for hyperbilirubinemia. Nine % of all newborns on average were said to require phototherapy. It is postulated that the UV light generates free radical oxidation which can cause double strand breaks in chromosomal DNA. Interestingly, the DNA repair mechanisms are found to not be fully developed in newborns as is also the concentration of melanin protein which protects skin from overexposure to UV light. Any system that could potentially limit the amount of phototherapy to that which can successfully deplete peripheral levels of bilirubin to normal levels without overexposure would be very beneficial. A review of CCSI's technology does in fact allow for this as where the Spectrx system does not. CCSI's technology allows for the monitoring of bilirubin levels during phototherapy which then allows for just the optimal amount of therapy. In contrast, Spectrx's technology requires multiple endpoints and individual reads making it nearly impossible to provide optimal phototherapy. Today, the amount of time for phototherapy is more less standardized with overexposure. There are many other benefits of using CCSI's device; all of which dramatically cut health care costs but I thought this is one that has been overlooked and needs to be further explored. Roger